- Japan
- /
- Healthcare Services
- /
- TSE:9987
Suzuken Co., Ltd. (TSE:9987) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Last week, you might have seen that Suzuken Co., Ltd. (TSE:9987) released its annual result to the market. The early response was not positive, with shares down 2.4% to JP¥5,104 in the past week. Revenues of JP¥2.4t were in line with forecasts, although statutory earnings per share (EPS) came in below expectations at JP¥455, missing estimates by 3.8%. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.
We've discovered 2 warning signs about Suzuken. View them for free.Taking into account the latest results, the most recent consensus for Suzuken from four analysts is for revenues of JP¥2.50t in 2026. If met, it would imply a satisfactory 4.4% increase on its revenue over the past 12 months. Statutory earnings per share are forecast to fall 12% to JP¥422 in the same period. Before this earnings report, the analysts had been forecasting revenues of JP¥2.49t and earnings per share (EPS) of JP¥361 in 2026. There was no real change to the revenue estimates, but the analysts do seem more bullish on earnings, given the solid gain to earnings per share expectations following these results.
See our latest analysis for Suzuken
There's been no major changes to the consensus price target of JP¥5,700, suggesting that the improved earnings per share outlook is not enough to have a long-term positive impact on the stock's valuation. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. Currently, the most bullish analyst values Suzuken at JP¥6,600 per share, while the most bearish prices it at JP¥5,100. With such a narrow range of valuations, the analysts apparently share similar views on what they think the business is worth.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Suzuken's past performance and to peers in the same industry. The analysts are definitely expecting Suzuken's growth to accelerate, with the forecast 4.4% annualised growth to the end of 2026 ranking favourably alongside historical growth of 2.7% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 4.4% annually. Suzuken is expected to grow at about the same rate as its industry, so it's not clear that we can draw any conclusions from its growth relative to competitors.
The Bottom Line
The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Suzuken following these results. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for Suzuken going out to 2028, and you can see them free on our platform here.
Don't forget that there may still be risks. For instance, we've identified 2 warning signs for Suzuken that you should be aware of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:9987
Suzuken
Primarily engages in the distribution of pharmaceuticals in Japan and internationally.
Flawless balance sheet, undervalued and pays a dividend.
Market Insights
Community Narratives

